Skip to main content
. 2024 Apr 12;23(4):479–489. doi: 10.1007/s10689-024-00370-7

Fig. 5.

Fig. 5

RNA expression in sulindac and erlotinib treated colon organoids (A) RNA expression of MYC, EGR1, IL33, FOSL1, LGR5 and FOXQ1 in control (C) and sulindac (S) treated organoids derived from uninvolved colon from SPS, FAP, Lynch and control patient cohorts. Bar graphs show the mean and standard error (n = 4–6) of normalized read counts for each gene. (B) RNA expression of MYC, EGR1, IL33, FOSL1, LGR5 and FOXQ1 in control (C) and erlotinib + sulindac combination (ES) treated organoids derived from SSLs from SPS patients and APs from FAP patients. Bar graphs show the mean and standard error (n = 4–6) of normalized read counts for each gene. Statistical significance determined by DESeq2, FDR < 0.05